Charlotte Teunissen Professor clinical chemistry from the Nederlands
Teunissen, Charlotte E.
Teunissen, Charlotte Elisabeth, 1971-
Teunissen, C.E. (Charlotte Elisabeth), 1971-
VIAF ID: 316790707 (Personal)
Permalink: http://viaf.org/viaf/316790707
Preferred Forms
- 100 0 _ ‡a Charlotte Teunissen ‡c Professor clinical chemistry from the Nederlands
-
-
-
- 100 1 _ ‡a Teunissen, Charlotte E.
-
- 100 1 _ ‡a Teunissen, Charlotte E.
- 100 1 _ ‡a Teunissen, Charlotte E.
-
- 100 1 _ ‡a Teunissen, Charlotte Elisabeth ‡d 1971-
- 100 1 _ ‡a Teunissen, Charlotte Elisabeth, ‡d 1971-
4xx's: Alternate Name Forms (6)
5xx's: Related Names (1)
Works
Title | Sources |
---|---|
Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases | |
Cerebrospinal fluid in clinical neurology | |
Hersenspiegelingen | |
hierarchy of coupled sleep oscillations reverses with aging in humans | |
Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status | |
Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds | |
Maximizing the Potential of Longitudinal Cohorts for Research in Neurodegenerative Diseases: A Community Perspective | |
The metabolic syndrome in a memory clinic population: relation with clinical profile and prognosis. | |
Microbleeds relate to altered amyloid-β metabolism in Alzheimer's disease. | |
Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab | |
Monocyte-derived tissue transglutaminase in multiple sclerosis patients: reflecting an anti-inflammatory status and function of the cells? | |
A multi-center study of neurofilament assay reliability and inter-laboratory variability | |
Multi-tracer model for staging cortical amyloid deposition using PET imaging | |
Neurofilament ELISA validation. | |
Neurofilament stoichiometry simulations during neurodegeneration suggest a remarkable self-sufficient and stable in vivo protein structure | |
Neurofilaments as biomarkers in neurological disorders | |
New CSF biomarkers on the block | |
Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency | |
Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics. | |
A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease | |
Nutritional status and structural brain changes in Alzheimer's disease: The NUDAD project | |
Optimizing patient care and research: the Amsterdam Dementia Cohort. | |
Oxysterols and cholesterol precursors correlate to magnetic resonance imaging measures of neurodegeneration in multiple sclerosis. | |
Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study | |
Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project | |
Plasma Amyloid-β | |
The plasma peptidome | |
Plasma proteome in multiple sclerosis disease progression | |
Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers. | |
A Practical Guide to Immunoassay Method Validation | |
Preclinical AD predicts decline in memory and executive functions in subjective complaints | |
Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers | |
Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease | |
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis | |
Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. | |
Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset | |
Proteolytic shedding of the macrophage scavenger receptor CD163 in multiple sclerosis | |
Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset | |
Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42. | |
Regulator of oligodendrocyte maturation, miR-219, a potential biomarker for MS. | |
Retinal thickness as a potential biomarker in patients with amyloid-proven early- and late-onset Alzheimer's disease. | |
Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. | |
Role of BRI2 in dementia | |
Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study | |
Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy | |
Selective impairment of hippocampus and posterior hub areas in Alzheimer's disease: an MEG-based multiplex network study | |
Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers. | |
Serum leptin is not altered nor related to cognitive decline in Alzheimer's disease | |
Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study | |
Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome | |
Sex differences in CSF biomarkers vary by Alzheimer's disease stage and APOE ε4 genotype | |
Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease-Data from three memory clinic studies | |
Standard biobanking conditions prevent evaporation of body fluid samples | |
Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid β((1-42)), Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop | |
Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative | |
Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results | |
Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease. | |
Systemic and intrathecal immune activation in association with cerebral and cognitive outcomes in paediatric HIV | |
Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1-42) in human cerebrospinal fluid | |
Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. | |
Towards an in vitro diagnosis for neurodegeneration | |
An update on the genetics of dementia with Lewy bodies | |
Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 years | |
Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study | |
Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort | |
Validation of soluble amyloid-β precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases. | |
Variability of CSF Alzheimer's disease biomarkers: implications for clinical practice | |
Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia. | |
White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. | |
α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies |